Aduhelm (Aducanumab-avwa): Dosage, Administration, and Important Considerations

Understanding Aduhelm (Aducanumab-avwa) Dosage and Administration for Alzheimer's Disease

Alzheimer's disease, a progressive neurodegenerative disorder, affects millions worldwide, impacting memory, thinking, and behavior. While there is no cure, treatments aim to manage symptoms and slow disease progression. Aduhelm, with the active ingredient aducanumab-avwa, is a prescription medication developed to treat early stages of Alzheimer's disease, specifically in individuals experiencing mild cognitive impairment or mild dementia. This blog post provides a comprehensive overview of Aduhelm's dosage, how it is administered, and crucial factors to consider for patients in India and globally.

What is Aduhelm?

Aduhelm is a biologic drug belonging to the class of monoclonal antibodies. It is designed to target and help clear amyloid plaques in the brain, a hallmark of Alzheimer's disease. It is crucial to understand that Aduhelm is intended for individuals in the early phases of the disease and is administered intravenously (IV) by a qualified healthcare professional.

Aduhelm Dosage Schedule and Strengths

Aduhelm comes in a liquid solution with a strength of 100 mg/mL. The dosage is carefully determined based on the patient's body weight and administered according to a specific schedule to gradually increase the dose, allowing the body to adapt and minimize potential side effects. The dosing schedule is as follows:

• Doses 1 and 2: 1 mg per kilogram (kg) of body weight.
• Doses 3 and 4: 3 mg per kg of body weight.
• Doses 5 and 6: 6 mg per kg of body weight.
• Dose 7 and beyond (Maintenance Dose): 10 mg per kg of body weight.

This gradual escalation in dosage is a critical aspect of Aduhelm therapy. It helps healthcare providers monitor the patient's response and manage potential adverse reactions effectively. The maintenance dose of 10 mg/kg is typically given every 4 weeks.

How Aduhelm is Administered

Aduhelm is not a medication that can be taken at home. It is administered as an intravenous (IV) infusion, meaning it is injected into a vein over a period of time. The infusion process is carried out by a healthcare professional, such as a doctor or nurse, at a hospital or clinic setting. Each infusion typically lasts about 1 hour.

The administration schedule involves receiving an infusion once every 4 weeks. This regular schedule is important for maintaining therapeutic levels of the drug in the body and for consistent monitoring by healthcare providers.

Importance of Regular Dosing and Rescheduling Missed Appointments

Consistency is key in Aduhelm treatment. Patients are advised to adhere strictly to the scheduled infusions. If a patient misses an appointment for an Aduhelm dose, it is essential to contact the doctor's office as soon as possible to reschedule. The manufacturer recommends that doses be given at least 21 days apart to ensure safety and efficacy.

Monitoring and Potential Side Effects

Before starting Aduhelm treatment, doctors typically perform an MRI scan of the brain. This baseline scan helps assess the patient's condition. Furthermore, brain MRI scans are conducted periodically throughout the treatment to monitor for specific changes, particularly related to Amyloid-Related Imaging Abnormalities (ARIA). ARIA can manifest as swelling or bleeding in the brain and is a significant consideration in Aduhelm therapy.

If a patient experiences certain side effects, including ARIA detected on an MRI scan, the doctor may adjust the dosage or the frequency of administration. Close monitoring by healthcare professionals is paramount to ensure patient safety and optimize treatment outcomes.

Current Status of Aduhelm

It is important for patients and healthcare providers to be aware of the latest developments regarding Aduhelm. The manufacturer of Aduhelm, Biogen, has discontinued the production and sales of the drug. This means that Aduhelm is no longer commercially available. If Aduhelm was prescribed to you, it is crucial to consult your doctor immediately to discuss alternative treatment options for Alzheimer's disease.

When to Consult a Doctor

Given the discontinuation of Aduhelm, any patient who was previously prescribed this medication should consult their doctor without delay. Your doctor can provide guidance on:

• Alternative Treatments: Discussing other available medications and therapies for managing Alzheimer's disease.
• Clinical Trial Information: If you participated in a clinical trial for Aduhelm, your study team can provide specific information and support.
• Ongoing Care: Ensuring continuity of care and management of Alzheimer's symptoms.

Disclaimer: This information is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.